VIGL Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -- compared to Vigil Neuroscience's net margin of 19.72%. Vigil Neuroscience's return on equity of -- beat Gilead Sciences's return on equity of 32.29%.

Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 18.02%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Vigil Neuroscience has higher upside potential than Gilead Sciences, analysts believe Vigil Neuroscience is more attractive than Gilead Sciences.

Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Vigil Neuroscience quarterly revenues are --, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Vigil Neuroscience's net income of -$22.4M is lower than Gilead Sciences's net income of $1.3B. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

HOOKIPA Pharma has a net margin of -- compared to Vigil Neuroscience's net margin of -769.81%. Vigil Neuroscience's return on equity of -- beat HOOKIPA Pharma's return on equity of -105.43%.

Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 18.02%. On the other hand HOOKIPA Pharma has an analysts' consensus of $2.00 which suggests that it could grow by 75.44%. Given that HOOKIPA Pharma has higher upside potential than Vigil Neuroscience, analysts believe HOOKIPA Pharma is more attractive than Vigil Neuroscience.

Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HOOKIPA Pharma has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.599%.

Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HOOKIPA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. HOOKIPA Pharma pays out -- of its earnings as a dividend.

Vigil Neuroscience quarterly revenues are --, which are smaller than HOOKIPA Pharma quarterly revenues of $2M. Vigil Neuroscience's net income of -$22.4M is lower than HOOKIPA Pharma's net income of -$15.4M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while HOOKIPA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 1.53x for HOOKIPA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology has a net margin of -- compared to Vigil Neuroscience's net margin of -2214.55%. Vigil Neuroscience's return on equity of -- beat Predictive Oncology's return on equity of -557.45%.

Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 18.02%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 283%. Given that Predictive Oncology has higher upside potential than Vigil Neuroscience, analysts believe Predictive Oncology is more attractive than Vigil Neuroscience.

Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.559%.

Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

Vigil Neuroscience quarterly revenues are --, which are smaller than Predictive Oncology quarterly revenues of $110.3K. Vigil Neuroscience's net income of -$22.4M is lower than Predictive Oncology's net income of -$2.4M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 3.62x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Protagenic Therapeutics has a net margin of -- compared to Vigil Neuroscience's net margin of --. Vigil Neuroscience's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

Vigil Neuroscience has a consensus price target of $9.52, signalling upside risk potential of 18.02%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6392.75%. Given that Protagenic Therapeutics has higher upside potential than Vigil Neuroscience, analysts believe Protagenic Therapeutics is more attractive than Vigil Neuroscience.

Vigil Neuroscience has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

Vigil Neuroscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vigil Neuroscience pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Vigil Neuroscience quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Vigil Neuroscience's net income of -$22.4M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Vigil Neuroscience's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vigil Neuroscience is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.